A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2022-10-31

Target enrollment:

Participant gender:

This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.

Phase 2

Maxinovel Pty., Ltd.